Jean Marc Regimbeau1, Cyril Cosse2, Gernot Kaiser3, Catherine Hubert4, Christophe Laurent5, Real Lapointe6, Helen Isoniemi7, Rene Adam8. 1. Digestive and Oncological Surgery Department, Amiens University Medical Center, Amiens, France; EA 4292, Jules Verne University of Picardy, Amiens, France; Clinical Research Center, Amiens University Medical Center, Amiens, France. Electronic address: regimbeau.jean-marc@chu-amiens.fr. 2. Digestive and Oncological Surgery Department, Amiens University Medical Center, Amiens, France; Clinical Research Center, Amiens University Medical Center, Amiens, France. 3. Essen University Hospital, Essen, Germany. 4. UCL Saint Luc, Brussels, Belgium. 5. Saint Andre Hospital, Bordeaux, France. 6. CHUM, Saint Luc Hospital, Montreal, Canada. 7. Transplantation and Liver Surgery Helsinki University Hospital, Helsinki, Finland. 8. Centre Hépato-Biliaire, Assistance Publique - Hôpitaux de Paris (APHP), Hôpital Universitaire Paul Brousse, Villejuif, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 935, Villejuif, France.
Abstract
BACKGROUND: The combination of liver resection and chemotherapy has become the standard of care for colorectal liver metastases (LM). The objective of the present study was to evaluate the impact of two-stage hepatectomy (TSH) on the long-term survival of patients with bilobar LM. METHODS: We included adult (over-18) patients from the LiverMetSurvey registry with confirmed multiple colorectal LM and having undergone either one-stage hepatectomy or TSH with curative intent. The "TSH (2/2)" group (n = 625) comprised patients having completed both stages of TSH; the "TSH (1/2)" group (n = 244) comprised patients having undergone only the first stage of TSH; the "hepatectomy" group. The primary outcome criterion was the overall survival (OS). The secondary outcomes were the morbidity and mortality rates. RESULTS: The 30- and 90-day mortality rates were respectively 3.8% and 9.3% in the TSH (2/2) group, 9.4% and 16.4% in the TSH (1/2) group, and 5.4% and 9.1% in the "hepatectomy" group. The three-year OS rate was 45% in the TSH (2/2) group, 30% in the TSH (1/2) group and 50.7% in the hepatectomy group. CONCLUSION: The LiverMetSurvey registry's data indicate that TSH is associated with rather good long-term survival and acceptable morbidity and mortality rates.
BACKGROUND: The combination of liver resection and chemotherapy has become the standard of care for colorectal liver metastases (LM). The objective of the present study was to evaluate the impact of two-stage hepatectomy (TSH) on the long-term survival of patients with bilobar LM. METHODS: We included adult (over-18) patients from the LiverMetSurvey registry with confirmed multiple colorectal LM and having undergone either one-stage hepatectomy or TSH with curative intent. The "TSH (2/2)" group (n = 625) comprised patients having completed both stages of TSH; the "TSH (1/2)" group (n = 244) comprised patients having undergone only the first stage of TSH; the "hepatectomy" group. The primary outcome criterion was the overall survival (OS). The secondary outcomes were the morbidity and mortality rates. RESULTS: The 30- and 90-day mortality rates were respectively 3.8% and 9.3% in the TSH (2/2) group, 9.4% and 16.4% in the TSH (1/2) group, and 5.4% and 9.1% in the "hepatectomy" group. The three-year OS rate was 45% in the TSH (2/2) group, 30% in the TSH (1/2) group and 50.7% in the hepatectomy group. CONCLUSION: The LiverMetSurvey registry's data indicate that TSH is associated with rather good long-term survival and acceptable morbidity and mortality rates.
Authors: R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho Journal: Clin Transl Oncol Date: 2019-07-29 Impact factor: 3.405
Authors: R Rhaiem; R Kianmanesh; M Minon; A Tashkandi; A Aghaei; G Ledoux; Ch Hoeffel; O Bouche; D Sommacale; T Piardi Journal: World J Surg Date: 2020-05 Impact factor: 3.352
Authors: Roberto Cannella; Adele Taibbi; Salvatore Pardo; Giuseppe Lo Re; Ludovico La Grutta; Tommaso Vincenzo Bartolotta Journal: BJR Open Date: 2019-04-29
Authors: Mariana I Chavez; Sepideh Gholami; Bradford J Kim; Georgios A Margonis; Cecilia G Ethun; Susan Tsai; Kathleen K Christians; Callisia Clarke; Harveshp Mogal; Shishir K Maithel; Timothy M Pawlik; Michael I D'Angelica; Thomas A Aloia; Daniel Eastwood; T Clark Gamblin Journal: Ann Surg Oncol Date: 2021-01-03 Impact factor: 5.344